5 takeaways on the global hospital acquired disease testing market

From 2016 to 2022, the global hospital acquired disease testing market is expected to continue expanding, a Credence Research report found, according to Run Direct Magazine.

Here are five takeaways:

1. By 2022, the market is expected to hit $1.63 billion.

2. The market was valued at $523 million last year.

3. In 2015, the hospital-acquired pneumonia and urinary tract infection segment collaboratively had a 50 percent market share.

4. North America has the largest regional presence in the market due to a high number of hospital stays and prevalence of healthcare-acquired infections.

5. Diatherix, Roche, Cantel Medical, Qiagen, Cephid and bioMeriux are key market vendors.

More articles on quality & infection control:
10% boost in hand hygiene compliance reduced HAIs by 6%: 4 takeaways
3 tips when disclosing medical errors
Valeritas names Erick Lucera new CFO — 5 points

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 


Patient Safety Tools & Resources Database

Featured Webinars

Featured Whitepapers

Featured Podcast